Workflow
Blood Volume Analysis (BVA)
icon
Search documents
Daxor Corporation Announces New Data from Duke University and Highlights Key BVA Insights at American College of Cardiology's 74th Annual Scientific Session and Expo
GlobeNewswire News Room· 2025-04-02 12:00
Core Insights - Daxor Corporation showcased its blood volume measurement technology at the American College of Cardiology (ACC) 74th Annual Scientific Session, highlighting new findings from Duke University that confirm blood volume analysis (BVA) as a more accurate measure of congestion in heart failure patients [1][2] - The session titled "When Pressure ≠ Volume" attracted over 400 clinicians, emphasizing the growing awareness and recognition of BVA in the cardiology community [2] - Research from Duke University indicated that traditional proxy markers for volume care do not correlate with intravascular volume, reinforcing the need for precision in managing congestion in heart failure [3] Company Overview - Daxor Corporation is a leader in blood volume measurement technology, having developed the BVA-100® (Blood Volume Analyzer), the only FDA-cleared diagnostic blood test for quantifying blood volume status [5] - Over 65,000 tests have been conducted at leading hospitals in the U.S., significantly improving hospital performance metrics and reducing mortality and readmissions in heart failure and critical care [5] - The company is engaged in ongoing trials for heart failure treatment with support from the NIH and is developing analyzers for combat casualty care in collaboration with the U.S. Department of Defense [5]
Daxor Corporation Announces New Data from Duke University and Highlights Key BVA Insights at American College of Cardiology's 74th Annual Scientific Session and Expo
Newsfilter· 2025-04-02 12:00
Core Insights - Daxor Corporation showcased its blood volume measurement technology at the American College of Cardiology (ACC) 74th Annual Scientific Session, highlighting new findings from Duke University that confirm blood volume analysis (BVA) as a more accurate measure of congestion in heart failure patients [1][2] - The session titled "When Pressure ≠ Volume" attracted over 400 clinicians, emphasizing the growing awareness and recognition of BVA in the cardiology community [2] - Research from Duke University indicated that traditional proxy markers for volume care do not correlate with true intravascular volume, reinforcing the need for precision in managing heart failure [3] Company Overview - Daxor Corporation is a leader in blood volume measurement technology, having developed the BVA-100® (Blood Volume Analyzer), the only FDA-cleared diagnostic blood test for quantifying blood volume status [5] - Over 65,000 tests have been conducted at leading hospitals in the U.S., significantly improving outcomes in heart failure and critical care by reducing mortality and readmissions [5] - The company is engaged in ongoing trials for heart failure treatment with support from the NIH and is developing analyzers for combat casualty care in collaboration with the U.S. Department of Defense [5]